Inside the KLOW Stack: The Four Peptides that make up the KLOW peptide blend

In plain English

The klow stack is four separate research peptides in one vial. That sentence is the most important thing to understand about KLOW peptide: it is not one compound. It is four chemically distinct peptides — KPV, GHK-Cu, BPC-157, and TB-500 — dissolved together at fixed amounts.

The four are not random. The composition logic is that they occupy four different nodes in the biology of tissue repair: KPV dials down inflammation; GHK-Cu rebuilds the matrix around the repair site; BPC-157 drives the new blood-vessel supply that healing tissue needs; and TB-500 helps cells migrate across the wound site. These four steps are complementary — not redundant, not redundant with each other.

Here is what the research does and does not say: each of these four peptides has a body of individual studies behind it. The combination has zero controlled studies. Everything said about what KLOW does as a blend is extrapolation from the individual research. This page lays out each component in plain language, with its evidence and its honest limits.

KLOW

KLOW is a co-formulated research blend — four peptides co-lyophilized at fixed ratios in one vial. The most widely cited composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. 'KLOW' is not a registered pharmaceutical name; no FDA-approved KLOW product exists. The blend is a research-only co-formulation.

The four components do not fuse into a new molecule. They remain four distinct chemical species in solution, each with its own pharmacokinetic profile, its own target tissue, and its own half-life. The vial co-delivers them — it does not merge them.

KPV — the anti-inflammatory arm

Structure: L-Lys-L-Pro-L-Val (CAS 67727-97-3, MW 342.44 Da). The C-terminal tripeptide of alpha-melanocyte-stimulating hormone (residues 11–13). Sequence: Lysine-Proline-Valine.

Mechanism: KPV is actively transported into intestinal epithelial cells and macrophages via PepT1 (SLC15A1), the di/tripeptide transporter upregulated in inflamed gut tissue. At nanomolar concentrations it inhibits NF-kappaB nuclear import and MAPK (ERK/p38) signaling and reduces secretion of TNF-alpha, IL-6, IL-1beta, and IL-8 ^[3]. Its anti-inflammatory action in peritonitis was characterized as mechanistically distinct from core alpha-MSH peptides — likely directed at IL-1beta function, independent of melanocortin receptors ^[9].

Research evidence: Oral KPV reduced the severity of DSS- and TNBS-induced colitis in mice ^[3]. KPV-treated mice in an IBD adoptive-transfer model showed earlier recovery and reduced myeloperoxidase activity, with activity retained in MC1R-deficient animals ^[10]. PepT1-targeted KPV nanoparticle formulations in colitis models further improved outcomes relative to non-targeted delivery ^[8][12].

Limits: No approved KPV monotherapy. No published human pharmacokinetic or efficacy trial.

GHK-Cu — the matrix and transcriptome arm

Structure: Gly-His-Lys chelated 1:1 to Cu(II) (CAS 89030-95-5, MW 402.92 Da). Naturally present in human plasma at approximately 200 ng/mL at age 20, declining to ~80 ng/mL by age 60 ^[4]. First isolated from human plasma by Loren Pickart in 1973.

Mechanism: Stimulates synthesis of procollagen I and IV, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin in fibroblasts at nanomolar concentrations. Modulates approximately 31% of human protein-coding genes at a 50%-or-greater threshold, with strongest signals on extracellular-matrix remodeling, DNA repair, antioxidant defense, and the ubiquitin-proteasome system ^[5]. Reduces colitis severity through the SIRT1/STAT3 pathway and restores the epithelial barrier ^[13]. Supplies copper(II) for lysyl oxidase (the copper-dependent enzyme that crosslinks collagen and elastin).

Research evidence: Topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in placebo-controlled topical data ^[4]. Decades of topical cosmetic and wound-healing human data; no approved systemic indication.

Limits: GHK-Cu's human data are topical and cosmetic. No approved systemic product. At 50 mg/80 mg vial share, copper(II) load is the highest of any peptide stack in this class — a consideration for anyone with copper-handling disorders such as Wilson's disease.

BPC-157 — the angiogenic and tissue-repair arm

Structure: Synthetic 15-amino-acid peptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS 137525-51-0, MW 1419.53 Da). Derived from a partial sequence of a protein identified in human gastric juice.

Mechanism: Activates VEGFR2 phosphorylation with downstream PI3K/Akt/eNOS signaling — the primary angiogenic axis. Upregulates the growth-hormone receptor in tendon fibroblasts. Modulates the nitric-oxide system in a manner partly resistant to L-NAME inhibition, suggesting a distinct NO route ^[2].

Research evidence: BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures at doses of 10 micrograms, 10 nanograms, and 10 picograms per rat intraperitoneally once daily ^[2]. A 2025 first-in-human IV pilot in two adults administered 10–20 mg intravenously with no adverse events ^[6]. A 2025 narrative review addressed BPC-157's safety framing ^[14].

Limits: Extensive rodent tissue-repair literature; very limited human data (n=2 in the safety pilot). FDA placed BPC-157 in category 2 of the 503A bulk-substances review.

TB-500 — the cytoskeletal and wound-closure arm

Structure: Synthetic N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (MW 889.02 Da). The LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4. TB-500 is the synthetic fragment; thymosin beta-4 (Tbeta4) is the full-length native protein.

Mechanism: The LKKTET motif sequesters G-actin (monomeric globular actin), a step linked to cell migration and re-epithelialization. Full-length thymosin beta-4 additionally activates integrin-linked kinase and mobilizes epicardial progenitor cells — activities established for the native protein, not demonstrated for the TB-500 fragment.

Research evidence: In a rat full-thickness wound model, native thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline; increased wound contraction by at least 11%; and raised collagen deposition and angiogenesis ^[1]. As little as 10 picograms stimulated keratinocyte migration 2–3-fold in vitro ^[1]. A 2024 review confirmed Tbeta4's effects are mediated through pro-resolving inflammation pathways ^[11]. A 2025 study showed Tbeta4-exosome hydrogels enhanced vascularized wound healing ^[15].

Limits: Most efficacy data are for full-length thymosin beta-4, not the TB-500 fragment. A 2026 sports medicine review noted scarce human safety data and regulatory concerns for TB-500 ^[7]. TB-500 is prohibited at all times under the WADA Prohibited List (S2) ^[7].

Why four peptides in one vial — the combination rationale

The combination rationale is mechanistic: four arms addressing four complementary steps in the same repair cascade. KPV reduces the inflammatory signal that would otherwise slow repair. GHK-Cu rebuilds the matrix that repaired tissue needs to hold its structure. BPC-157 builds the new blood vessels that bring nutrients to the repair site. TB-500 moves cells across the injury to close the wound.

Whether these four arms produce a meaningful synergy when co-dosed in a single vial is the unanswered question. No controlled study has tested KLOW against any subset. A pharmacokinetic mismatch is inherent — the four components have different half-lives and cannot all be at matched exposures simultaneously. The combination rationale is coherent; the combination evidence is absent.

This is what this site — and the KLOW research readout — makes explicit.